Longitudinal Plasma Proteomics for Psoriasis Biomarkers During Secukinumab Therapy

92 inflammation-related plasma proteins were quantified from 10 patients with moderate-to-severe psoriasis and 10 healthy controls before and during secukinumab therapy. The dataset, created by Hongyang Zhang and last updated in April 2026, provides molecular evidence for systemic immunomodulatory effects. It highlights candidate circulating biomarkers like CXCL1, CXCL5, CCL20, HGF, and IL-17C for disease diagnosis and treatment response monitoring.

Use Cases

• Identify diagnostic plasma protein signatures for psoriasis based on baseline proteomic profiles.
• Analyze longitudinal changes in inflammatory mediators like CCL20 and IL-17C following IL-17A inhibitor therapy.
• Correlate baseline biomarker levels, such as IL-17C, with clinical disease severity scores.
• Explore biological pathways, including cytokine-cytokine receptor interactions, enriched in differentially expressed proteins.

Strengths

• Includes longitudinal data from patients before and during treatment, allowing for temporal analysis.
• Quantifies 92 specific inflammation-related proteins using the Olink Target 96 panel.
• Validates key findings with an independent method (ELISA).
• Dataset is openly shared under a CC-BY-4.0 license.

Limitations

• The sample size is small, with data from only 10 patients and 10 controls.
• Row count and column-level documentation are unknown, limiting suitability assessment.
• Data may reflect bias inherent to the specific cohort and study design.

Provenance

Source

figshare, author Hongyang Zhang.

Collection Method

Plasma samples were analyzed using the Olink Target 96 Inflammation panel; longitudinal patterns were assessed with Mfuzz clustering.

Freshness

Last updated 2026-04-24 05:40:18; freshness should be verified.